Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants Gabe 2024 Diabetes, Obesity and Metabolism Wiley Online Library Updates in Medicine REDEFINE 2: CagriSema in T2D + Obesity Original article link in bio Phase 3a RCT in 1206 adults with T2D (BMI 27, HbA1c 710%) Instagram Cagrilintide is an amylin analogue that helps regulate appetite. In a randomized trial of over 3400 patients who were overweight or obese and had 1 weight related complication, individuals assigned to a combination Cagrilintide is a novel, long acting peptide designed to target multiple receptors involved in appetite regulation and energy balance. Unlike traditional weight loss medications that often target a single pathway, cagrilintide acts as Weight Loss Efficacy of Cagrilintide and Semaglutide gutsandgrowth